Status:
COMPLETED
Creatine Safety & Tolerability in Huntington's Disease
Lead Sponsor:
Massachusetts General Hospital
Conditions:
Huntington's Disease (HD)
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to extend findings from the creatine dose-finding study (CREST-UP1) in Huntington's disease to evaluate the long-term safety, tolerability, and clinical impact of high dos...
Detailed Description
PRÉCIS Protocol Title Creatine Safety \& Tolerability in Huntington's Disease (CREST-X): A Single-Center, Open-Label, Long-Term Safety \& Tolerability Extension Study of Creatine in Subjects with HD ...
Eligibility Criteria
Inclusion
- Individuals who have completed the CREST-UP1 study.
- Individuals who are able to take oral medication.
- Individuals capable of providing informed consent and complying with trial procedures.
Exclusion
- History of known sensitivity or intolerability to creatine.
- Clinical evidence of unstable medical illness in the investigator's judgment.
- Additional eligibility criteria apply.
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2011
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01412151
Start Date
April 1 2005
End Date
November 1 2011
Last Update
March 9 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Charlestown, Massachusetts, United States, 02129